A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia

PHASE1CompletedINTERVENTIONAL
Enrollment

52

Participants

Timeline

Start Date

December 1, 2006

Primary Completion Date

February 1, 2010

Study Completion Date

June 1, 2010

Conditions
Chronic Lymphocytic LeukemiaLeukemia, B-Cell, Chronic
Interventions
DRUG

lenalidomide

DRUG

lenalidomide

DRUG

lenalidomide

DRUG

lenalidomide

DRUG

lenalidomide

Trial Locations (35)

8036

Hospital Clinic Provincial de Barcelona, Servicio de Hematología, Institute of Haematology and Oncology, Villaroel, 170, Barcelona

10021

Weill Medical College of Cornell University, Division of Hematology & Oncology, New York

12203

Charité, Campus Benjamin Franklin, Medizinische Klinik III, Hindenburgdamm 30

13210

SUNY Upstate Medical Center, Syracuse

14263

Roswell Park Cancer Institute, Buffalo

16132

Clinica Ematologica- A.O.U. San Martino, Clinica Ematologica Dipartimento di Medicina Interna, Genova

19090

Abington Hematology Oncology Assoc., Inc., Willow Grove

24116

University of Schleswig Holstein, Director Medizinische Klinik II, Campus Kiel, Chemnitzstrasse 33, Kiel

27157

Wake Forest University School of Medicine, Winston-Salem

30060

Northwest Georgia Oncology Centers, PC., Wellstar Health System, Marietta

32207

Baptist Cancer Institute, Jacksonville

34461

Cancer & Blood Disease Center, Lecanto

44195

The Cleveland Clinic Foundation, Cleveland

48201

Karmanos Cancer Institute/Wayne State University School of Medicine, Detroit

50924

Uniklinik Köln, Klinik I für Innere Medizin, Klinisches Studienzentrum Hämatologie, Bettenhaus Ebene 04, Raum 001/048, Kerpener Str. 62

60611

Robert H. Lurie Comprehensive Cancer Center, Chicago

71130

LSU Health Sciences Center, Feist-Weiller Cancer Center, Shreveport

77030

University of Texas MD Anderson Cancer Center, Houston

83712

Mountain States Tumor Institute, Boise

85724

Arizona Cancer Center, Tucson

89081

University of Ulm, Abteilung Innere Medizin III, Robert-Koch-Strasse 8, Ulm

92270

Desert Hematology Oncology Medical Group, Inc., Rancho Mirage

94704

Alta Bates Summit Comprehensive Cancer Center, Berkeley

98104

Swedish Cancer Institute, Seattle

60637-1470

University of Chicago Medical Center, Chicago

46202-5149

Indiana University Medical center, Indianapolis

T6G 1Z2

Cross Cancer Institute, Edmonton

R3E 0V9

Cancer Care Manitoba, Winnipeg

L8V 5C2

Juravinski Cancer Centre, Hamilton

N6C 6B5

London Helath Science Centre, London

S7N 4H4

Saskatoon Cancer Centre, Saskatoon

141 86

Karolinska Universitetssjukhuset, Hematologiskt Centrum, Karolinska Universitetssjukhuset,, Stockholm

LS9 7TF

St James's Institute of Oncology, Dept. of Haematology, Level 3, Bexley Wing, Beckett Street, Leeds

EC1A 7BE

Bart's and the London NHS Trust, St. Bartholomew's Hospital, 7th Floor Gloucester House, Cancer Services, London

M20 4BX

Christie Hospital NHS Foundation Trust, Haematology and Transplant Unit,, Manchester

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Celgene

INDUSTRY

NCT00419250 - A Dose Escalation Study of Lenalidomide in Relapsed or Refractory B-cell Chronic Lymphocytic Leukemia | Biotech Hunter | Biotech Hunter